Are insulin resistance, type 2 diabetes, and central obesity linked to lower testosterone and impaired gonadal steroidogenesis?

Clinical evidence

• Clinical and epidemiological data demonstrate that insulin resistance, type 2 diabetes, and central obesity are strongly associated with lower serum testosterone levels in men.
• Approximately one-third to one-half of men with type 2 diabetes present with functional hypogonadotropic hypogonadism, characterized by low testosterone coupled with inappropriately normal or low luteinizing hormone levels.
• This relationship is highly bidirectional: metabolic dysfunction suppresses the hypothalamic-pituitary-gonadal (HPG) axis, while lower testosterone levels further promote visceral adiposity and worsen insulin resistance.

Mechanistic explanations

• Metabolic syndrome and insulin-resistant states directly impair testicular Leydig cell function and gonadal steroidogenesis.
• Chronic hyperinsulinemia in insulin-resistant states induces the expression of the orphan nuclear receptor DAX-1 in Leydig cells.
• Elevated DAX-1 acts as a transcriptional repressor of key steroidogenic genes, notably steroidogenic acute regulatory protein (StAR/Stard1) and CYP11A1, thereby limiting cholesterol transport into the mitochondria and directly reducing testosterone synthesis.
• Furthermore, local lipotoxicity, oxidative stress, and inflammatory signaling in testicular tissues directly damage the structural and functional integrity of Leydig cells.

Bottom line

• Key takeaway: Strong clinical and molecular evidence confirms that insulin resistance, type 2 diabetes, and central obesity are associated with lower testosterone and impaired gonadal steroidogenesis. This occurs through a bidirectional cycle of central HPG axis suppression and direct, DAX-1-mediated transcriptional repression of the Leydig cell steroidogenic pathway.